Company news

AlzeCure Pharma AB news in 2026

AlzeCure Pharma AB's news releases, calls and decks from 2026, newest first.

View company

AlzeCure Pharma Publishes Updated Company Presentation Following the Eli Lilly and QuantumCell Agreements

September 18, 2026

AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15

September 8, 2026

AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly

August 18, 2026

AlzeCure Receives a Total Upfront Payment of USD 12 million and Completes the Initial Transaction with QuantumCell

August 12, 2026

AlzeCure Pharma Resolves on a Directed Share Issue to QuantumCell

August 3, 2026

AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project

July 1, 2026

Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026

June 29, 2026

AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project

June 9, 2026

AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document

June 5, 2026

Notice To Annual General Meeting in AlzeCure Pharma AB

May 26, 2026

AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million

April 24, 2026

Last Patient has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856

April 20, 2026

AlzeCure Pharma Publishes its Annual Report for 2025

April 8, 2026

AlzeCure Pharma to Present at Redeye Healthcare Day on April 14

April 7, 2026

AlzeCure Pharma to Present at Redeye Alzheimer's Theme Event on April 9

April 1, 2026

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD

March 19, 2026

AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11

March 4, 2026

AlzeCure Publishes its Year-End Report for January - December 2025

February 26, 2026

Pain Project ACD440 Granted Orphan Drug Status in the EU

February 24, 2026

AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026

February 3, 2026

AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam

February 2, 2026

Decks in 2026